



Safyral[®] (drospirenone/ethinyl estradiol/levomefolate) – First-time generic

- On August 31, 2017, Sandoz launched an authorized generic version of Bayer Healthcare's [Safyral \(drospirenone/ethinyl estradiol/ levomefolate\)](#) tablets, indicated for use by women to prevent pregnancy, and in women who choose to use an oral contraceptive as their method of contraception, to raise folate levels for the purpose of reducing the risk of a neural tube defect in a pregnancy conceived while taking the product or shortly after discontinuing the product.
 - In addition, Teva has received FDA approval of an [AB-rated](#) generic version of Safyral. Launch plans are pending for this product.
- Safyral carries a boxed warning for cigarette smoking and serious cardiovascular events.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.